Baidu
map

Nature:可重启肿瘤抑制因子的新型非编码RNA

2013-10-12 佚名 手牵手博客站

日前,来自哈佛医学院等机构的科学家们发现了一种新型非编码 RNA,它能够"重启"癌细胞中被抑制的肿瘤抑制因子。相关研究论文刊登在了近期出版的《自然》(Nature)杂志上。 【原文下载】 该研究首次揭示了 DNA 甲基化过程中的关键酶 DNMT1( DNA methyl transferase 1)与 RNA 的关系,为治疗癌症等疾病开辟了新的道路。 DNA 甲基化过程能通过化学修饰 DNA

日前,来自哈佛医学院等机构的科学家们发现了一种新型非编码 RNA,它能够"重启"癌细胞中被抑制的肿瘤抑制因子。相关研究论文刊登在了近期出版的《自然》(Nature)杂志上。 【原文下载】 该研究首次揭示了 DNA 甲基化过程中的关键酶 DNMT1( DNA methyl transferase 1)与 RNA 的关系,为治疗癌症等疾病开辟了新的道路。 DNA 甲基化过程能通过化学修饰 DNA ,而不是影响 DNA 序列本身达到调控基因表达的作用。DNA 甲基化往往与基因沉默相关,在很多疾病中都有发现 DNA 甲基化现象。如在癌症中,癌细胞的抑癌基因就通过 DNA 甲基化而被抑制。 在这项研究在,科学家将焦点放在了一类特异影响抑癌基因 CEBPA 的非编码 RNA.CEBPA 沉默与急性骨髓性白血病,肺癌和其他类型癌症都相关。研究发现非编码 RNA 能够结合 DNMT1 从而防止 CEBPA 的甲基化。该原理有望能够"重启"被下调的抑癌因子,而该原理很可能在其他数千个基因中同样适用。 研究人员表示,新发现的非编码 RNA 能够特异的抑制 DNA 甲基化,引入 RNA 能够选择性的去甲基化

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879686, encodeId=204a18e968680, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 09 05:58:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809123, encodeId=a78d180912330, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Mar 02 21:58:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718788, encodeId=46a41e1878813, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Thu May 29 09:58:00 CST 2014, time=2014-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743409, encodeId=ad431e4340944, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Dec 05 08:58:00 CST 2013, time=2013-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532070, encodeId=9d2415320e004, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584611, encodeId=92aa1584611f7, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
    2014-05-09 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879686, encodeId=204a18e968680, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 09 05:58:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809123, encodeId=a78d180912330, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Mar 02 21:58:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718788, encodeId=46a41e1878813, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Thu May 29 09:58:00 CST 2014, time=2014-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743409, encodeId=ad431e4340944, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Dec 05 08:58:00 CST 2013, time=2013-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532070, encodeId=9d2415320e004, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584611, encodeId=92aa1584611f7, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879686, encodeId=204a18e968680, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 09 05:58:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809123, encodeId=a78d180912330, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Mar 02 21:58:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718788, encodeId=46a41e1878813, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Thu May 29 09:58:00 CST 2014, time=2014-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743409, encodeId=ad431e4340944, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Dec 05 08:58:00 CST 2013, time=2013-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532070, encodeId=9d2415320e004, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584611, encodeId=92aa1584611f7, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1879686, encodeId=204a18e968680, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 09 05:58:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809123, encodeId=a78d180912330, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Mar 02 21:58:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718788, encodeId=46a41e1878813, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Thu May 29 09:58:00 CST 2014, time=2014-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743409, encodeId=ad431e4340944, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Dec 05 08:58:00 CST 2013, time=2013-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532070, encodeId=9d2415320e004, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584611, encodeId=92aa1584611f7, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
    2013-12-05 d830384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1879686, encodeId=204a18e968680, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 09 05:58:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809123, encodeId=a78d180912330, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Mar 02 21:58:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718788, encodeId=46a41e1878813, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Thu May 29 09:58:00 CST 2014, time=2014-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743409, encodeId=ad431e4340944, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Dec 05 08:58:00 CST 2013, time=2013-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532070, encodeId=9d2415320e004, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584611, encodeId=92aa1584611f7, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1879686, encodeId=204a18e968680, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri May 09 05:58:00 CST 2014, time=2014-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809123, encodeId=a78d180912330, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun Mar 02 21:58:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1718788, encodeId=46a41e1878813, content=<a href='/topic/show?id=ea4782939b8' target=_blank style='color:#2F92EE;'>#肿瘤抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82939, encryptionId=ea4782939b8, topicName=肿瘤抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c1b32641457, createdName=lxg962, createdTime=Thu May 29 09:58:00 CST 2014, time=2014-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743409, encodeId=ad431e4340944, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Thu Dec 05 08:58:00 CST 2013, time=2013-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532070, encodeId=9d2415320e004, content=<a href='/topic/show?id=43d454921d1' target=_blank style='color:#2F92EE;'>#抑制因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54921, encryptionId=43d454921d1, topicName=抑制因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e90612318044, createdName=shalley70, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584611, encodeId=92aa1584611f7, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]

相关资讯

PLOS ONE:胚胎发育与肿瘤的关联

   MicroRNAs(miRNAs)是长度约22个核苷酸的非编码小分子RNA,调节多种重要的生理和病理过程,包括胚胎发育和肿瘤发生。许多研究阐述了miRNAs在肿瘤发生与胚胎发育过程中具有重要作用,而目前,对于胚胎发育与肿瘤发生之间的关联研究非常有限。近期,武汉大学郭明雄副教授,领衔其团队,对胚胎发育过程与癌症发生之间的miRNAs进行了系统研究,研究成果发表在8月刊的 P

专家:相当数量肿瘤患者疼痛没得到很好控制

世界卫生组织于2000年明确提出“慢性疼痛是一类疾病”。国际疼痛学会决定从2004年开始,将每年的10月11日定为“世界镇痛日”。今年的10月11日是第十个“世界镇痛日”。北京大学肿瘤医院中西医结合科主任医师李萍萍在接受中新网健康频道采访时表示,疼痛在肿瘤中是一种最常见的症状,疼痛治疗和控制实际上是肿瘤治疗的一个重要部分,肿瘤患者应意识到不需要忍受,客观的表达疼痛可以使医生更好的治疗,使疼痛得到很

PLoS One:中科院解析肿瘤细胞端粒保护

近代物理研究所辐射医学研究室与日本国立放射医学研究中心科研人员开展的合作研究发现,肿瘤细胞染色体末端端粒的保护状态直接影响其对重离子辐射的敏感性。 端粒是细胞染色体末端的高度重复序列,对染色体结构起着重要的维持与保护作用。端粒长度的缩短及其结构的异常变化是细胞衰老以及死亡的一个重要诱因。在正常细胞中,端粒由于端粒酶的失活随着每次细胞分裂逐渐变短;而在肿瘤细胞中,由于端粒酶的异常激活,其端粒长度

Adv Mat & JACS:癌细胞捕获与释放研究取得新进展

癌细胞与材料表面的相互作用是生物界面化学研究中的前沿热点之一,对肿瘤诊断、抗癌药物筛选等研究具有重要意义。在国家自然科学基金委、科技部和中国科学院的大力支持下,中国科学院化学研究所有机固体重点实验室的科研人员,在生物界面上癌细胞的特异识别与粘附调控方面取得了重要进展。 受免疫细胞与肿瘤细胞的特异粘附界面启发,相关实验人员不再将细胞简化成理想的球体,而是还原其多尺度性,提出了结构匹配和分子识别的协

PLoS One:新研究证明血液测试能检测癌转移

来自德国哥廷根大学兽医学研究所和美国Chronix生物医学公司的科研人员发表了一项探索犬乳腺癌的遗传标记的新的研究。发表在同行评审的《公共科学图书馆 综合》(PLOS ONE)杂志上的这篇论文识别出了人类和犬乳腺肿瘤的重要相似之处和差别,为使用犬模型系统的未来研究提供了一个强有力的平台。 【原文下载】 作为该项目的一部分,这组科研人员成功地实施了Chronix生物医学公司的检测见于血液无

JCO:肿瘤早期萎缩情况可预测含西妥昔单抗一线治疗的转移性结直肠癌患者长期结局

研究要点: 本研究针对进行CRYSTAL与OPUS随机试验,考察了肿瘤早期萎缩与患者的长期结局间的关系。 通过第8周时的影像学评价结果、时间依赖性受试者工作特征、Cox回归模型以及亚群治疗效果模式图分析进行了考察。 EFS与通过化疗与西妥昔单抗联合方案一线治疗的KRAS野生型mCRC患者长期结局间存在显著关联。 通过ETS ≥ 20%(v < 20%)的区分阈值可将患者群体划分为存在

Baidu
map
Baidu
map
Baidu
map